The first-generation RAF inhibitors, Vemurafenib [305,306], Dabrafenib [307], and Encorafenib [308], were developed and applied to treatment of BRAF(V600E)-harboring cancers as single agents or together with MEK inhibitors. Here, MAP2K7 is linked to cancer.